Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M, Ungewiss J, Haase C, Robillard L, Simmons AD, Harding TC, Nguyen M. Zboralski D, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2621-2635. doi: 10.1007/s00259-023-06211-6. Epub 2023 Apr 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37086273 Free PMC article.
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, Kwan T, Lin KK, Lenore J, Harding TC, Xiao J, Simmons AD, Mohan AM, Beindorff N, Reineke U, Smerling C, Osterkamp F. Zboralski D, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3651-3667. doi: 10.1007/s00259-022-05842-5. Epub 2022 May 24. Eur J Nucl Med Mol Imaging. 2022. PMID: 35608703 Free PMC article.
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Baum RP, et al. Among authors: zboralski d. J Nucl Med. 2022 Mar;63(3):415-423. doi: 10.2967/jnumed.120.259192. Epub 2021 Jun 24. J Nucl Med. 2022. PMID: 34168013 Free PMC article.
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM. Roccaro AM, et al. Among authors: zboralski d. Cell Rep. 2014 Oct 9;9(1):118-128. doi: 10.1016/j.celrep.2014.08.042. Epub 2014 Sep 25. Cell Rep. 2014. PMID: 25263552 Free PMC article.
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M. Ludwig H, et al. Among authors: zboralski d. Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074071 Free PMC article. Clinical Trial. No abstract available.
15 results